# US 2025/0207152 A1 · Casz compositions and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0207152 A1
- Document ID: US20250207152A1
- Status: Published application
- Kind: A1
- Application number: 18/393,318
- Filed: 2023-12-21
- Published: 2025-06-26
- Earliest claimed: 2017-11-01
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: Jennifer A. Doudna; David Burstein; Janice S. Chen; Lucas B. Harrington; David Paez-Espino; Jillian F. Banfield
- Web page: https://patentgrep.com/patent/US20250207152A1

## CPC

- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12Q 1/6816: characterised by the detection means (C12Q1/6804 takes precedence)
- C12N 9/1007: {Methyltransferases (general) (2.1.1.)}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 15/102: {Mutagenizing nucleic acids}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N 15/86: Viral vectors
- C12N 15/907: {in mammalian cells}
- C12Q 1/6809: Methods for determination or identification of nucleic acids involving differential detection
- C07K 2319/09: containing a nuclear localisation signal
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2800/80: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided are compositions and methods that include one or more of: (1) a “CasZ” protein (also referred to as a CasZ polypeptide), a nucleic acid encoding the CasZ protein, and/or a modified host cell comprising the CasZ protein (and/or a nucleic acid encoding the same); (2) a CasZ guide RNA that binds to and provides sequence specificity to the CasZ protein, a nucleic acid encoding the CasZ guide RNA, and/or a modified host cell comprising the CasZ guide RNA (and/or a nucleic acid encoding the same); and (3) a CasZ transactivating noncoding RNA (trancRNA) (referred to herein as a “CasZ trancRNA”), a nucleic acid encoding the CasZ trancRNA, and/or a modified host cell comprising the CasZ trancRNA (and/or a nucleic acid encoding the same).

## Claims

### Claim at position 1

1-86. (canceled)

### Claim 87

A method of modifying a target locus of interest comprising delivering to said locus:
a) a CRISPR associated (Cas) polypeptide or a nucleic acid encoding the Cas polypeptide; and
b) a guide nucleic acid or DNA molecule encoding the guide nucleic acid, the guide nucleic acid comprising:
i) a first sequence that is capable of being bound by the Cas polypeptide, and
ii) a second sequence that hybridizes to a target sequence of a target nucleic acid, wherein the target sequence is a eukaryotic sequence,
wherein the target sequence is adjacent to a PAM of 5′-TTTN-3′, wherein T is thymine and N is any nucleotide.

### Claim 88 (depends on 87)

The method of claim 87, wherein the Cas polypeptide recognizes a PAM of 5′-TTTR-3′, wherein T is thymine and R is selected from guanine and adenine.

### Claim 89 (depends on 87)

The method of claim 87, wherein the Cas polypeptide is a variant of a polypeptide according to SEQ ID NO: 3 that has reduced nucleic acid cleavage activity relative to the polypeptide according to SEQ ID NO: 3.

### Claim 90 (depends on 87)

The method of claim 87, wherein the Cas polypeptide is fused to a heterologous protein, and wherein the heterologous protein has an enzymatic activity selected from: DNA repair activity, DNA damage activity, deamination activity, dismutase activity, alkylation activity, depurination activity, oxidation activity, pyrimidine dimer forming activity, integrase activity, transposase activity, recombinase activity, polymerase activity, ligase activity, helicase activity, photolyase activity, and glycosylase activity.

### Claim 91 (depends on 89)

The method of claim 89, wherein the Cas polypeptide is fused to a heterologous protein, and wherein modifying the target locus comprises introducing, removing, or altering an epigenetic modification of the target locus.

### Claim 92 (depends on 89)

The method of claim 89, wherein the Cas polypeptide is linked to a methyltransferase.

### Claim 93 (depends on 89)

The method of claim 89, wherein the Cas polypeptide comprises at least one amino acid substitution in a RuvC domain.

### Claim 94 (depends on 87)

The method of claim 87, wherein the Cas polypeptide is catalytically inactive.

### Claim 95 (depends on 87)

The method of claim 87, wherein the Cas polypeptide comprises at least one amino acid substitution at an aspartic acid residue or a glutamic acid residue relative to a protein that is 100% identical to SEQ ID NO: 3.

### Claim 96 (depends on 95)

The method of claim 95, wherein the at least one amino acid substitution is located in a RuvC domain.

### Claim 97 (depends on 87)

The method of claim 87, wherein the Cas polypeptide comprises at least one amino acid substitution that is selected from an amino acid corresponding to D405, E586 and D684 of SEQ ID NO: 39, and any combination thereof, wherein the amino acid sequence of the engineered polypeptide is aligned with SEQ ID NO: 39 for greatest percent identity.

### Claim 98 (depends on 97)

The method of claim 97, comprising modifying the target locus of interest in a cell.

### Claim 99 (depends on 98)

The method of claim 98, wherein the cell is a eukaryotic cell.

### Claim 100 (depends on 99)

The method of claim 99, wherein the eukaryotic cell is selected from a stem cell, a germ cell, a fibroblast, an oligodendrocyte, a glial cell, a hematopoietic cell, a neuron, a muscle cell, a bone cell, a hepatocyte, a pancreatic cell, a myofibroblast, a cardiac myoblast, a skeletal myoblast, and a T cell.

### Claim 101 (depends on 87)

The method of claim 87, comprising modifying the target locus of interest in a human subject.

### Claim 102 (depends on 101)

The method of claim 101, comprising delivering the nucleic acid encoding the Cas polypeptide and the guide nucleic acid to the human subject via a lipid nanoparticle.

### Claim 103 (depends on 102)

The method of claim 102, wherein the nucleic acid encoding the Cas polypeptide comprises a messenger RNA.

### Claim 104 (depends on 103)

The method of claim 103, comprising delivering the nucleic acid encoding the Cas polypeptide and the DNA molecule encoding the guide nucleic acid to the human subject via an adeno-associated viral vector.

### Claim 105 (depends on 87)

The method of claim 87, comprising delivering a donor nucleic acid to said locus.

### Claim 106

A composition comprising:
a) a Cas polypeptide or a nucleic acid encoding the Cas polypeptide; and
b) a guide nucleic acid or DNA molecule encoding the guide nucleic acid, the guide nucleic acid comprising:
i) a first sequence that is capable of being bound by the polypeptide, and
ii) a second sequence that hybridizes to a target sequence of a target nucleic acid, wherein the target sequence is a eukaryotic sequence,
wherein the target sequence is adjacent to a PAM of 5′-TTTN-3′, wherein T is thymine and N is any nucleotide.
